A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
NCT06010004 on ClinicalTrials.gov · last registry update 2026-06-30
Finished 5 June 2025, after enrolling 401 people. Primary outcome, as filed: Number of Participants With Treatment Emergent Adverse Events (TEAEs). orforglipron is approved in the US, but not for type 2 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P3
- Drug
- orforglipronFoundayo
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 401
- Started
- 2023-09-28
- Primary completion
- 2025-06-05 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the orforglipron page for this molecule’s full trial and approval history.